Bioanalytické studium nádorových markerů karcinomu prostaty na úrovni RNA a proteinu

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Bioanalytical study of tumour markers for prostate carcinoma at RNA and protein level
Authors

GUMULEC Jaromír MASAŘÍK Michal KŘÍŽKOVÁ S. BABULA P. HRABEC Roman ROVNÝ Arne MASAŘÍKOVÁ M. ADAM V. ECKSCHLAGER T. KIZEK René

Year of publication 2011
Type Article in Periodical
Magazine / Source Praktický lékař
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords tumour diseases; polymerase chain reaction; electrochemistry; immunodetection; molecularly-biological techniques; tumour markers
Description Current methods for diagnosis of prostate carcinoma do not enable us to distinguish aggressive tumours (significant tumours) from clinically latent tumours (non-significant tumours). This study aims to determine levels of potential clinically important tumour markers such as - alpha-methyl CoA-racemase (AMACR), - caveolin-1, - metallothionein (MT), - p53, - NF-kB, - c-FOS, - c-JUN, - Ki-67, - prostate-specific antigen (PSA), ZIP1 and ZnT-1 in prostatic tissue represented by 22Rv1 (tumour) and PNT1A (healthy) cell lines and in blood serum of patients with histologically evaluated adenocarcinoma (82 tumour patients and 51 healthy volunteers). Based on mRNA expression, it was found that Cav-1, NF-kB, c-FOS and c-JUN were down-regulated and MT,AMACR, PSA, Ki-67, MMP-9 and zinc transporters ZIP1 and ZnT-1 were up-regulated. In serum, the level of MT was significantly enhanced above 1 microM. Caveolin-1 levels were significantly increased in high-grade tumours, which points to the possibility of using this protein as a marker for the aggressive form of prostate carcinoma.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.